GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $1,021,160.89 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,559 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $96.71, for a total transaction of $1,021,160.89. Following the completion of the sale, the chief executive officer now owns 14,865 shares of the company’s stock, valued at $1,437,594.15. This represents a 41.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.

GeneDx Stock Down 3.9 %

Shares of WGS opened at $90.79 on Wednesday. The company has a 50-day simple moving average of $84.57 and a 200-day simple moving average of $70.78. The firm has a market capitalization of $2.55 billion, a P/E ratio of -46.32 and a beta of 1.91. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, equities research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System raised its position in GeneDx by 13.3% in the fourth quarter. California State Teachers Retirement System now owns 11,384 shares of the company’s stock worth $875,000 after purchasing an additional 1,335 shares in the last quarter. Polar Asset Management Partners Inc. acquired a new position in GeneDx in the fourth quarter worth about $1,007,000. Palisades Investment Partners LLC acquired a new position in GeneDx in the fourth quarter worth about $6,425,000. Castleark Management LLC acquired a new position in GeneDx in the fourth quarter worth about $4,743,000. Finally, PharVision Advisers LLC acquired a new position in GeneDx in the fourth quarter worth about $301,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on WGS shares. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group boosted their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.